0000358654
Donate

Reimbursement status:
No reimbursement

Cancer: Lymphocytic leukaemia

Indication:

Inotuzumab ozogamicin is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22- positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+ ) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).

Reimbursement information:

EPAR/SmPC

Details

ATC category :
L01XC
L01XC Monoclonal antibodies
EMA approval status :
Approved
EMA approval date :
2017-06-29
EMA conditional? :
No
EMA orphan? :
Yes
EMA biological? :
Yes